United Community Banks has shown improvement in deposits, loans, and income, leading to an upgrade from 'sell' to a soft ...

Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The ...

In a report released on February 27, David Evans from Kepler Capital maintained a Hold rating on UCB SA (0NZT – Research Report), with a price ...

United Community Banks, Inc. ( NYSE:UCB ) will pay a dividend of $0.24 on the 4th of April. This means that the ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how the company is creating a culture based around ‘design ...

UCB has a 52 week low of $110.35 and a 52 week high of $200.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. 10 Stocks to Sell NOW!

United Community Banks Inc is a financial services provider. The company functions through the Union Community Bank, which provides retail and corporate banking services, including checking, savings, ...

UCB’s Bimzelx is firmly on physicians’ radars ... The market intelligence company found half of the physicians had trialed Bimzelx in PsA. Spherix compared the level of activity favorably ...